Rapid Micro Biosystems to Participate in the Stifel 2025 Healthcare Conference

Rhea-AI Summary

Rapid Micro Biosystems (Nasdaq: RPID) will participate in the Stifel 2025 Healthcare Conference in New York. Management is scheduled for a 30-minute question-and-answer session with the host analyst on Tuesday, November 11, 2025 at 11:20 a.m. ET. A live webcast will be available on the company investor relations website and the webcast will be archived for replay after the event.

News Market Reaction

+1.39%

1 alert

+1.39% News Effect

+$2M Valuation Impact

$132M Market Cap

0.3x Rel. Volume

On the day this news was published, RPID gained 1.39%, reflecting a mild positive market reaction. This price movement added approximately $2M to the company's valuation, bringing the market cap to $132M at that time.

Data tracked by StockTitan Argus on the day of publication.

LEXINGTON, Mass., Oct. 30, 2025 (GLOBE NEWSWIRE) -- Rapid Micro Biosystems, Inc. (Nasdaq: RPID) (the “Company”), an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products, today announced that the Company will participate in the Stifel 2025 Healthcare Conference in New York, NY.

Company management is scheduled to participate in a 30-minute question-and-answer session with the host analyst on Tuesday, November 11, 2025, at 11:20 a.m. ET. A live webcast will be available on the Rapid Micro Biosystems investor relations website at https://investors.rapidmicrobio.com/ and can be accessed here. The webcast will be archived and available for replay after the event.

About Rapid Micro Biosystems

Rapid Micro Biosystems is an innovative life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The Company’s flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (“MQC”) testing workflows used in the largest and most complex pharmaceutical manufacturing operations across the globe. The Growth Direct system brings the quality control lab to the manufacturing floor, unlocking the power of MQC automation to deliver the faster results, greater accuracy, increased operational efficiency, better compliance with data integrity regulations, and quicker decision making that customers rely on to ensure safe and consistent supply of important healthcare products. The Company is headquartered Lexington, Massachusetts and has U.S. manufacturing in Lowell, Massachusetts, with global locations in Switzerland, Germany, and the Netherlands. For more information, please visit www.rapidmicrobio.com or follow the Company on X (formerly known as Twitter) at @rapidmicrobio or on LinkedIn.

Investor Contact:
Michael Beaulieu, CFA
Vice President, Investor Relations and Corporate Communications
mbeaulieu@rapidmicrobio.com

Media Contact:
media@rapidmicrobio.com

FAQ

When will Rapid Micro Biosystems (RPID) present at the Stifel 2025 Healthcare Conference?

The company will present on Tuesday, November 11, 2025 at 11:20 a.m. ET.

How long is the Rapid Micro Biosystems (RPID) session at Stifel 2025?

Management is scheduled for a 30-minute question-and-answer session.

How can investors watch the Rapid Micro Biosystems (RPID) Stifel presentation live?

A live webcast will be available on the company's investor relations website at https://investors.rapidmicrobio.com/.

Will the Rapid Micro Biosystems (RPID) Stifel webcast be available after the event?

Yes, the webcast will be archived and available for replay after the event.

Who will host the Rapid Micro Biosystems (RPID) session at the Stifel 2025 Healthcare Conference?

The session will be a question-and-answer format with the host analyst, as scheduled by the conference organizers.